JP2022528067A5 - - Google Patents

Info

Publication number
JP2022528067A5
JP2022528067A5 JP2021557277A JP2021557277A JP2022528067A5 JP 2022528067 A5 JP2022528067 A5 JP 2022528067A5 JP 2021557277 A JP2021557277 A JP 2021557277A JP 2021557277 A JP2021557277 A JP 2021557277A JP 2022528067 A5 JP2022528067 A5 JP 2022528067A5
Authority
JP
Japan
Prior art keywords
amino acid
antibody
item
heavy chain
functional fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021557277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022528067A (ja
JP7607579B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2020/050217 external-priority patent/WO2020197400A1/en
Publication of JP2022528067A publication Critical patent/JP2022528067A/ja
Publication of JP2022528067A5 publication Critical patent/JP2022528067A5/ja
Application granted granted Critical
Publication of JP7607579B2 publication Critical patent/JP7607579B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021557277A 2019-03-27 2020-03-27 工学的に操作されたIgA抗体および使用方法 Active JP7607579B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962824864P 2019-03-27 2019-03-27
US62/824,864 2019-03-27
PCT/NL2020/050217 WO2020197400A1 (en) 2019-03-27 2020-03-27 Engineered iga antibodies and methods of use

Publications (3)

Publication Number Publication Date
JP2022528067A JP2022528067A (ja) 2022-06-08
JP2022528067A5 true JP2022528067A5 (https=) 2023-04-04
JP7607579B2 JP7607579B2 (ja) 2024-12-27

Family

ID=70190056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557277A Active JP7607579B2 (ja) 2019-03-27 2020-03-27 工学的に操作されたIgA抗体および使用方法

Country Status (9)

Country Link
US (4) US11059909B2 (https=)
EP (1) EP3947441A1 (https=)
JP (1) JP7607579B2 (https=)
KR (1) KR20220004979A (https=)
CN (1) CN114096559B (https=)
CA (1) CA3131705A1 (https=)
IL (1) IL286641B1 (https=)
SG (1) SG11202110626SA (https=)
WO (1) WO2020197400A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12139536B2 (en) * 2017-06-08 2024-11-12 Antibody Biopharm Inc. Guided combinational therapeutic antibody
BR112021014276A2 (pt) * 2019-01-22 2021-09-28 Genentech, Inc. Anticorpos iga isolados, moléculas de fusão igg-iga isoladas, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, para tratar um indivíduo, para aumentar a expressão de dímeros, trímeros ou tetrâmeros, para aumentar a produção de polímeros, para aumentar a produção de dímeros, para aumentar a produção de um polímero, para diminuir a produção de polímeros, para aumentar a expressão transitória de um anticorpo, para expressar dímeros de moléculas de fusão, para expressar dímeros, trímeros ou tetrâmeros, para purificar um anticorpo, para purificar um estado oligomérico de um anticorpo, composição farmacêutica e uso do anticorpo
CN114096559B (zh) * 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法
CN115461363A (zh) * 2020-05-01 2022-12-09 诺华股份有限公司 免疫球蛋白变体
WO2023056240A2 (en) 2021-09-28 2023-04-06 Frontaim Biomedicines, Inc. Multiple formats of molecular complexes
CA3263303A1 (en) * 2022-08-04 2024-02-08 Lyell Immunopharma, Inc. METHODS FOR MANUFACTUREING CHIMERICAL ANTIGENIC RECEPTOR T LYMPHOCYTES
JP2026511056A (ja) * 2023-03-21 2026-04-10 ルング・バイオテクノロジー・パブリック・ベネフィット・コーポレイション 同種遺伝子療法のためのバイシストロニック構築物
AU2024315062A1 (en) * 2023-07-28 2026-03-12 Tigatx, Inc. Engineered iga antibodies and methods of use
CN120141946B (zh) * 2025-05-16 2025-08-12 杭州市北京航空航天大学国际创新研究院(北京航空航天大学国际创新学院) 一种用于大气中二氧化硫硫同位素测量的采集装置及分析方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US670417A (en) 1899-08-30 1901-03-26 Cronk Hanger Co Hand-rake.
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE106249T1 (de) 1987-11-05 1994-06-15 Hybritech Inc Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
EP1212366B1 (en) 1999-07-30 2007-09-12 Medarex, Inc. Therapeutic compounds comprised of anti-fc receptor binding agents
US8372954B2 (en) 2000-12-22 2013-02-12 National Research Council Of Canada Phage display libraries of human VH fragments
AU2002310497A1 (en) 2001-06-20 2003-01-08 Caprion Pharmaceuticals Inc. Protein aggregation assays and uses thereof
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1514107B1 (en) 2002-06-03 2013-05-15 The Institute for Systems Biology Methods for quantitative proteome analysis of glycoproteins
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7894724B2 (en) 2005-03-31 2011-02-22 Ciena Corporation Method and apparatus for improving dual-polarization optical communication performance
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
EP1916257A1 (en) 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin GD2 peptide mimotopes for anticancer vaccination
US8313730B2 (en) 2006-12-13 2012-11-20 Michael R. Simon Treatment of celiac disease with IgA
US20090075378A1 (en) 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
GB0812478D0 (en) 2008-07-09 2008-08-13 Rolls Royce Plc An apparatus and a method of measuring erosion of an edge of a turbomachine aerofoil
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
AU2015200990B2 (en) * 2009-03-20 2016-07-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
WO2010127369A1 (en) 2009-05-01 2010-11-04 Rational Biotechnology Inc. Eit (electrical impedance tomography) guided sonoporation, ultrasound tissue ablation and their use thereof
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
EP2578681B1 (en) 2010-05-24 2015-07-01 Kagoshima University Iga-binding peptide and iga purification using same
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
EP2465536A1 (en) 2010-12-14 2012-06-20 CSL Behring AG CD89 activation in therapy
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2791170A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
BR112014022240A2 (pt) 2012-03-09 2017-08-01 Csl Behring Ag composições compreendendo imunoglobulinas semelhantes à secretoras
PL3366705T3 (pl) * 2012-09-12 2023-09-18 Genzyme Corporation FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej
US9890216B2 (en) 2012-10-23 2018-02-13 Board Of Regents, The University Of Texas System Antibodies with engineered IgG Fc domains
DK3725807T3 (da) 2012-12-03 2026-01-12 Novimmune Sa Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
CN106456749B (zh) 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
US10925962B2 (en) 2014-07-18 2021-02-23 Nippi, Incorporated Polymeric IgA-type recombinant antibody and use thereof
CA3035427A1 (en) 2016-09-01 2018-03-08 Umc Utrecht Holding B.V. Cd20 antibodies
EP3747438A1 (en) 2017-07-24 2020-12-09 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction
EP3684818A2 (en) * 2017-09-21 2020-07-29 UMC Utrecht Holding B.V. Anti-gd2 antibody for the treatment of neuroblastoma
CN113260632A (zh) * 2018-10-29 2021-08-13 蒂嘉特克斯公司 包含IgA抗体构建体的组合物和方法
BR112021014276A2 (pt) 2019-01-22 2021-09-28 Genentech, Inc. Anticorpos iga isolados, moléculas de fusão igg-iga isoladas, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, para tratar um indivíduo, para aumentar a expressão de dímeros, trímeros ou tetrâmeros, para aumentar a produção de polímeros, para aumentar a produção de dímeros, para aumentar a produção de um polímero, para diminuir a produção de polímeros, para aumentar a expressão transitória de um anticorpo, para expressar dímeros de moléculas de fusão, para expressar dímeros, trímeros ou tetrâmeros, para purificar um anticorpo, para purificar um estado oligomérico de um anticorpo, composição farmacêutica e uso do anticorpo
CN114096559B (zh) * 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法

Similar Documents

Publication Publication Date Title
JP2022528067A5 (https=)
JP7273101B2 (ja) Cd38に結合する抗体治療剤
JP7379446B2 (ja) ヒトcd3結合抗体
JP7840511B2 (ja) 抗クローディン18抗体及びそれらの使用の方法
US11472880B2 (en) Humanized antibodies for CD3
CN104271602B (zh) 双特异性抗体
JP7397882B2 (ja) 二重特異性抗体及びその調製方法、使用
WO2015156268A1 (ja) 免疫活性化抗原結合分子
JP2023159380A (ja) PD-1とTGF-betaを標的とした四価二重特異性抗体、その製造方法および用途
CN116490210A (zh) Cd70抗体及其应用
JP7851303B2 (ja) ヒトcd3イプシロンに結合する新規なヒト抗体
JP2025083342A (ja) TGF-βRII結合タンパク質
CN119371536A (zh) 抗体和使用方法
WO2017162733A1 (en) Iga antibodies with enhanced stability
JP2024508597A5 (https=)
CN115698066A (zh) 抗cd47抗体及其用途
WO2021178253A1 (en) Anti-cd19 antibodies and methods of using and making thereof